Tablo power cord overheating alert shows how a simple instruction change becomes a PV control
FDA's early alert on Outset Medical's Tablo cords is a reminder that use-instruction updates depend on reporting, user follow-through and a clear view of what is still unknown.
What happened
On 18 November 2026, FDA's MedWatch channel published an early alert on Outset Medical's Tablo system. The company has told customers to inspect Tablo power cords before each use after reports of overheating at the connection between the cord and the inlet. According to the alert summary, no serious injuries or deaths have been reported so far.
The corrective measure is not a product removal. It is an update to the instructions for use, with a new pre-use inspection step added to the routine of whoever sets up and runs the device. The alert's own web address refers to updated use instructions for the Tablo console and the TabloCart prefiltration drawer. The summary available to us focuses on the power cord connection, so readers should check the full FDA notice for the exact scope.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- FDA early alert: Tablo power cord connections may overheat, Outset Medical updates instructions FDA MedWatch · Wed 18 Nov 2026
- EMA publishes list of Union reference dates and PSUR submission frequencies EMA · Wed 18 Nov 2026
- EU Health Security Committee urges stronger action on carbapenem-resistant bacteria as infections rise European Commission (DG SANTE) · Wed 18 Nov 2026
- AIFA starts rolling review of daraxonrasib after positive CHMP opinion in pancreatic cancer AIFA · Wed 18 Nov 2026
- Portugal's antibiotic use stays below EU average, but broad-spectrum prescribing remains a concern INFARMED · Wed 18 Nov 2026
- MHRA develops AdvanceGxP service to bring GxP advice into early innovation MHRA · Wed 18 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise
Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.
EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein
The EEA Joint Committee has added six feed additive acts, including a monensin sodium renewal and a Duddingtonia flagrans approval, to Annex I. Market access teams should read it as a lesson in how EU rules reach EEA markets.
Prescriber fraud plea and a week of enforcement signals: what QA and compliance should take from it
A Missouri physician and spouse admitted drug-prescribing and health care fraud conspiracies; alongside ANSM, BfArM and OIG actions, the day shows how oversight reaches every link in the chain.